Drugs /

dubermatinib

Back to Drugs List

Overview

NCI Definition [1]:
An orally available and selective inhibitor of the receptor tyrosine kinase AXL (UFO), with potential antineoplastic activity. Upon administration, TP-0903 targets and binds to AXL and prevents its activity. This blocks AXL-mediated signal transduction pathways and inhibits the epithelial-mesenchymal transition (EMT), which, in turn, inhibits tumor cell proliferation and migration. In addition, TP-0903 enhances chemo-sensitivity to certain other chemotherapeutic agents. AXL, a member of the Tyro3, AXL and Mer (TAM) family of receptor tyrosine kinases and overexpressed by many tumor cell types, plays a key role in tumor cell proliferation, survival, invasion and metastasis; its expression is associated with drug resistance and poor prognosis

Clinical Trials

View Clinical Trials for dubermatinib

Dubermatinib has been investigated in 4 clinical trials, of which 3 are open and 1 is closed. Of the trials investigating dubermatinib, 1 is phase 1 (1 open) and 3 are phase 1/phase 2 (2 open).

PML-RARA Fusion, t(15;17)(q22;q12), and t(15;17)(q24;q21) are the most frequent biomarker inclusion criteria for dubermatinib clinical trials.

Acute myeloid leukemia, chronic lymphocytic leukemia, and colorectal carcinoma are the most common diseases being investigated in dubermatinib clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Dubermatinib
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Dubermatinib
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating dubermatinib and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
2-((5-chloro-2-((4-((4-methylpiperazin-1-yl)methyl)phenyl)amino)pyrimidin-4-yl)amino)-n,n-dimethylbenzenesulfonamide, tp 0903, tp-0903, tp0903
Drug Target(s) [2]:
AXL
NCIT ID [1]:
C127116

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.